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The non-steroidal anti-inflammatory drugs in clinical use have been implicated with side effects on prolonged use.  
This implies the dearth of a safer alternative to these drugs and can be easily sourced from the huge resources available to us 
through Ayurveda. Tinospora cordifolia has been used in the preparation of traditional Ayurvedic formulations, with 
reported anti-inflammatory activities. Molecular docking studies have been used in an attempt to identify and elucidate the 
mechanism of action of the bioactive compounds in T. cordifolia with dual inhibition of 5-Lipoxygenase (5-LOX) and 
Cyclooxygenase-2 (COX-2) enzymes for identification of lead compounds. A screening of the compounds identified in the 
bioactive fraction of T. cordifolia was carried out using the drug-likeness score and the selected compounds were docked 
with the Glide module of Schrödinger suite 2014 with Maestro 9.3. Dihydroberberine (TC1) was found to be a potent 
inhibitor of both 5-Lipoxygenase and Cyclooxygenase-2 enzymes. The binding energy of the compounds to the free enzyme 
was better than when co-crystallized with substrate indicating preference to the enzyme active site. Dihydroberberine can be 
evaluated further as a promising candidate to develop a safer anti-inflammatory drug. 
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Medicinal plants have received wide publicity in 
recent times as a source of bioactive constituents that 
are better and effective than several accepted drugs 
currently in clinical use. The bioactive constituents  
of T. cordifolia have been reported with several 
medicinal properties including anti-diabetic effect 
reported by alkaloids particularly palmatine, 
jatrorrhizine and magnoflorine1, immunomodulatory 
functions of arabinogalactan as reported by Sharma  
et al.2 and Verma et al.3, immunopotentiating effects 
of cordioside, cordiofolioside A and cordial4. The 
adaptogenic properties of T. cordifolia validated with 
several research studies have highlighted the 
significance of the use of the plant extract in both 
traditional and modern ayurvedic preparations. 
Studies by the author on the anti-inflammatory 
activity of T. cordifolia have revealed dual inhibition 
of LOX and COX enzymes5 with inhibition in the 
production of pro-inflammatory cytokines, Tumour 
necrosis factor (TNF-) and Interleukin1 (IL-1)  
in lipopolysaccharide-induced dendritic cells. The 
constituents of the bioactive fraction were identified 
with Quadrupole Time of Flight Mass Spectrometry 
(QToFMS). The compounds identified were screened 
for Drug-likeness properties and the selected drug-
like compounds were docked in silico with enzymes, 
5-LOX and COX-2, involved in the production of 
pro-inflammatory leukotrienes and prostaglandins. 
In silico molecular docking studies predicts the 
preferential alignment of a target protein or nucleic 
acid to a ligand tso form a stable complex and these 
interactions are considered central to the signal 
transduction in biological systems6. Glide (Grid-
Based Ligand Docking with Energetics) distributed 
by Schrodinger is the molecular docking software 
designed to investigate the best conformation of a 
ligand, best pharmacophoric receptor site, and 
parameterized scoring function7. Several docking 
studies have been carried out in medicinal plants or its 
bioactive compounds to identify the most efficient lead 
compound for drug design. The study on curcuminoids 
from Curcuma longa reveals the binding orientation of 
the curcumin analogues in the active sites of COX 
thereby identifying potential lead compounds for novel 








Hazai et al.9 also reveals the high affinity of lycopene 
and lycophyll to the cleft at the interface of the β-barrel 
of 5-LOX indicating an allosteric mechanism in the 
proximity of the active center. The bioactive compound 
Tembetarinein T. cordifolia with anti-dermatophytic 
activity10 has been identified in independent in silico 
studies. In the present study effective dual inhibitors of 
LOX and COX enzymes were identified from the 
compounds in the bioactive fraction of  
T. cordifolia5 and further assessed for its Absorption, 
Distribution, Metabolism, Excretion and Toxicity 
(ADMET) properties. 
 
Materials and Methods 
 General Experimental Procedures The plant, T. cordifolia was collected from 
Kottayam, Kerala, India and identified by Jomy 
Augustine, taxonomist at the Department of Botany of 
St. Thomas College, Pala, India. The voucher number 
(JA17151) was obtained on submission of the voucher 
specimen at Kerala Forest Research Institute.  
All other chemicals used were of high purity 
analytical grade from HiMedia chemicals, India. 
Structural characterization of the bioactive methanol 
fraction was conducted in the Waters Xevo G2 QToF. 
For the in silico studies, the structures were drawn  
using ChemSketch from Advanced Chemistry 
Development, Inc. (ACD/Labs). Drug-likeness model 
score was computed with MolSoft32 software11. 
Molecular docking of lead compounds was calculated 
using the Schrodinger Suite 2014 with Maestro 9.3,12 
with LigPrep, Protein preparation wizard and Glide7. 
The ADMET studies were analysed using the Pre 
ADMET software13. 
 Identification of compounds from T. cordifolia and evaluation 
of dual LOX/COX inhibition The plant material comprising of the stem was used 
for the extraction of the bioactive methanol fraction 
from T. cordifolia as per the protocol described in 
Jacob et.al.5 and was evaluated for dual inhibition of 
both LOX isoenzymes and COX isoenzymes as 
described in Jacob et.al.5 was subjected to mass 
spectroscopic studies and the constituents of the 
bioactive fraction were identified as reported in  
Jacob et al.5. The compounds identified were labelled 
as TC1 to TC8 (supplementary file). 
 Screening of identified compounds for Molecular Properties 
and Drug Likeness The compounds, TC1-TC8, were screened for drug-
likeness and molecular properties calculated using the 
online prediction server Molsoft. The online server 
calculates the drug-likeness score based on the basic 
Lipinski’s rule of five applicable to drug candidates. 
The lipophilicity of the compounds is a measure of the 
permeability across cell membranes and is indicated by 
LogP. Polar surface area (PSA) is the measure of the 
surface area contributed by polar atoms and is 
calculated from the 3D structure of the compound. The 
molecular volume reflects on the characteristics of 
transport of the compounds in the body. These 
molecular properties can be used for screening 
potential drug-like candidates in the test compounds on 
comparison with known drugs.  
 Protein structure retrieval and preparation The target protein structures, retrieved from Protein 
Data Bank (http://www.rcsb.org/pdb/), were COX-2 
(PDB ID: 1CVU)14, 5-LOX (PDB ID: 3V99)15. 
Earlier enzyme kinetic studies16 have indicated that 
the enzyme exhibits mixed inhibition and can thereby 
bind to both the enzyme-substrate complex [ES] and 
the free enzyme [E]. The docking procedure was thus 
carried out in the presence/absence of substrate 
arachidonic acid (ACD) for both LOX/COX enzymes to 
determine the binding position of the inhibitor molecule 
and its affinity. The COX-2 PDB entry 1CVU contains 
co-crystallized ligands like ACD, -D-Mannose,  
N-Acetyl-D-Glucosamine etc. Docking in the presence 
of ACD was not possible for the 5-LOX protein (3V99) 
which had ACD as the only other co-crystallized ligand. 
Based on reported data on homology modelling by 
Pouplana et al.17, the LOX protein co-crystallized with 
RS7 ligand (2P0M) was used. 
 Preparation of Ligands and Proteins  The ligands were drawn using ChemSketch 
software from the Advanced Chemistry Development, 
Inc. (ACD/Labs). The LigPrep module of Schrodinger 
was used to prepare the ligand structures, generate 
variation and optimize the structures by minimizing 
energy levels. PDB structures of the enzymes were 
prepared using the Protein Preparation Wizard of 
Schrödinger Suite. The enzyme structure was pre-
processed and assigned bond orders were included, 
missing hydrogen atoms added and bond lengths/ 
angles were corrected. The pre-processed protein was 
then subjected to constrained IMPACT Protein 
Refinement (IMPREF) minimization and to the Root 
Mean Squared Deviation (RMSD) of 0.3 A°. 
 Receptor Grid Generation and Molecular Docking The grid was generated using co-crystallized ligand 
as the center of the grid. The ligands selected were 




ACD for the proteins 1CVU, 3V99 and RS7 for 
2P0M. RS7 was considered as the center of the grid 
because as described by Choi et al.18, it specifically 
binds to a location situated inside the substrate-
binding cavity of the enzyme. So, in effect, the same 
area is being used for docking studies. Docking of the 
ligand structures identified from bioactive fractions of 
T. cordifolia (TBF) by this author as reported earlier5  
to target proteins was performed with Glide 
(Schrodinger). The van der Waals radii were scaled by 
a factor of 0.819. The position of center of ligand  
was set as 10A° (Angstrom) docking sphere to 
accommodate maximum interaction of atoms. 
Molecular docking was performed on LOX inhibitors 
using the standard precision (SP) mode of Glide 
software. Glide scoring is based on a series of 
hierarchical filters for finding the possible binding 
locations of the ligand to the protein active site and the 
final scoring is done on the energy-minimized poses 
generated to find the Glide score. The binding energy 
of the ligands with the receptor was estimated using the 
automated Multi Ligand Bimolecular Association with 
Energetics (MBAE).  
 ADMET studies The pharmacokinetic descriptors of TC1 were 
determined by computational methods on the Pre 
ADMET web server13,20. The descriptors were 
grouped into two sections as the ADME prediction 
and the Toxicity prediction. The predictions were 
calculated based on quantitative structure activity 
relationship (QSAR) models using the molecular 
descriptors of known drugs. Oral drug absorption 
descriptors include the Caco2-cell model and the 
Madin-Darby canine kidney cell models. Drug 
delivery both oral and transdermal is predicted by the 
human intestinal absorption (HIA) and the skin 
permeability models, respectively. The efficacy of the 
drug can be further explained with the blood-brain 
barrier (BBB) penetration and plasma protein binding 
calculations. The prediction of the toxicity properties 
of TC1were completed with Ames Salmonella 




 Molecular Properties and Drug Likeness Themolecular properties of all the compounds and 
their drug-likeness scores (TC1 to TC9) are as 
indicated in (Table 1). Compounds TC4A, TC4B, 
TC9A and TC9B have a molecular weight greater 
than 500Da and with no other violations for all the 
other parameters except for LogP of TC5.Veber’s rule 
indicates that the PSA should not be more than 140A2 
for a good bioavailability of the drug candidate and all 
the compounds show effective PS values less than 
140A2,22,23. The drug-likeness score was calculated  
by MolSoft by combining the physicochemical, 
pharmacodynamic and pharmacokinetic properties for 
Table 1 — Molecular Properties and Drug-likeness Score of TC1 –TC9 
Descriptors TC1 TC2 TC3 TC4A TC4B TC5 TC6 TC7 TC8A TC8B TC9A TC9B 
Molecular 
weight 
337.13 268.13 345.32 522.25 522.25 417.38 514.26 468.24 358.2 358.2 550.36 550.35 
No of Hydrogen 
Bond Acceptor 
4 5 4 10 10 5 8 9 7 7 8 8 
No of Hydrogen 
Bond Donor 
0 1 3 4 4 4 0 2 1 1 4 3 
MolLogP 4.19 1.07 4.96 0.22 0.44 5.80 4.60 0.98 1.43 1.43 5.17 5.10 
MolLogS 
Log(moles/L) 




34.91 48.22 54.38 125.75 128.50 71.94 76.95 107.27 61.41 60.69 99.06 102.73 
Molecular 
Volume (A3) 
348.24 265.76 402.35 578.81 567.89 478.90 589.81 509.87 377.88 377.78 632.71 640.80 
No of stereo 
centers 
0 1 2 10 11 2 8 8 5 5 10 8 
Drug-likeness 
Score 
0.60 -0.18 -0.97 1.42 0.24 -1.26 -0.23 -0.07 -0.54 -0.45 0.26 1.08 
Status Active NA NA Active Active NA NA NA NA NA Active Active 
NA: Not active; indicates compounds that show a drug-likeness score less than zero and are unsuitable as drug candidates.  
 




all the compounds studied. The drug-likeness score 
with a value less than zero is considered as unsuitable 
for a drug. Five of the compounds TC1, TC4A, 
TC4B, TC9A and TC9B have a drug-likeness score 
greater than zero and have been considered for the 
molecular docking studies.  
 Docking of ligands with COX enzyme (1CVU) The results obtained after docking of COX enzyme 
with the five selected ligands are based on the Glide 
score, the binding energy, the H-bonding and the van der 
Waals interactions of the ligand-target complex.  
The ligand-protein complex will havea tighter bind for 
more negative values of the g-score, maximum 
hydrogen bonds and van der Waals interactions. The 
results of the molecular docking of COX enzyme are as 
shown in (Table 2). Of the five selected compounds only 
one, TC1 docked in the absence of ACD. The highest 
glide rankis for TC1 with no hydrogen bonds formed 
with neighbouring amino acids in the absence of ACD. 
In the presence of ACD, very weak hydrogen bonds are 
formed with neighbouring amino acids. The presence of 
Met522 in both the presence and absence of ACD 
indicates that the inhibitor is binding at the same 
location of COX enzyme (substrate-binding cavity).  
The results of the molecular docking of LOX enzymes 
are as shown in (Table 2). The affinity of the ligands for 
the LOX enzyme active site is very low with the highest 
rank is for TC1. Only one ligand TC1 has docked to the 
binding site of RS7 and enzyme but with a greater 
binding affinity as compared to the ACD docked 
enzyme. The docked pose is as shown in (Fig. 1A & B 
while Table 3) shows the neighbouring amino acids 
present in the docking site in each protein 
 ADMET Properties of TC1 The compound TC1 which shows the highest 
ranking for COX and LOX in the docking studies and 
was further evaluated for its ADMET properties. The 
results of ADMET studies are as given in (Table 4) 
Table 2 — Docking results for COX/LOX enzymes 
Sl. No. Name of Ligand Glide rank Glide Score 
COX without ACD substrate 
1 TC1 1 -9.43 
COX with ACD substrate 
1 TC1 1 -6.883 
2 TC9B 2 -5.13 
3 TC9A 3 -5.1 
4 TC4A 4 -4.68 
5 TC4B 5 -4.26 
LOX enzyme (3V99) without ACD 
1 TC1 1 -5.148 
2 TC9A 2 -5.049 
3 TC4B 3 -4.932 
 4 TC4A 4 -4.72 
5 TC9B 5 -4.46 
LOX enzyme (2P0M) without RS7 
1 TC1 1 -7.075 
 
Table 3 — Amino Acid Interactions of Best Ligand TC1 on docking of LOX and COX 
Target Docking Condition Name of Ligand Glide Score Amino Acid Residues in the Binding Pocket 
COX Without ACD TC1 -9.43 Met522, Gly526, Ala 527,Val523, Val349, Glu524, Met113, Leu531, 
Leu384, Ser530 
With ACD TC1 -6.883 Met522, His386, His388, Gln203, Trp387, Tyr385, Phe210, Ala207 
LOX Without ACD 
(3V99) 
TC1 -5.41 Asn 407, Phe 610, Gln 412, Leu188, Gln 609, Leu 179, Ile 406, 
Ala 410, Phe 177, His 367, Lys 409 
Without RS7 
(2P0M) 
TC1 -7.075 Val 409, Leu 408, Ile 593, His 545, Ala 404, Val 594, Phe 415, 
Gln 357, Ile 418 
 
Table 4 — Absorption Distribution Metabolism and Excretion 
(ADME) and Toxicity Properties of TC1 
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and indicates that TC1 has the potential of 
mutagenicity as per the Ames mutagenicity assay but 
is not carcinogenic, shows P-glycoprotein inhibition, 
low absorption in the central nervous system (CNS), 
medium permeability and strong plasma protein 
binding properties. 
 Discussion The bioactive fraction of T. cordifolia characterized and several compounds TC9 identified using UPLC-QToF mass spectrometry earlier5. The compounds identified in the bioactive 




was further named TC1-
fraction of T. cordifolia were characterized based on their molecular properties. The molecular properties were calculated based on Lipinski’s rudescribes parameters fulfilled by successful drug candidates with no more than one exception. The molecular weight of drugs (<500 daltons), the number of hydrogen bond donors (<5) and acceptors (<10), and the Partition coefficient (octanol(<5) are the factors considered desirable. The five compounds selected for molecular docking were purely based on the drug-likeness score which is based on the molecular descriptors. The molecular 
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docking studies were evaluated with the help of the docking grid area that allows the area for interaction of ligand and the target protein. The grid generation of the Glide program starts with the removal of the bound ligand at the center of the grid24. Docking strategy was performed with two objectives and in the first approach, the grid was selected with ACD as the center of the grid while in the second method alternative compounds, other than ACD were also considered in the preparation of the grid. The only PDB entry with co-crystallized ACD for 5-LOX is 3V99 which was initially used for the docking and a second PDB entry, 2P0M was used to explore the possibility of the binding of ligands to a second site on the target protein25 with RS7 as the co-crystallized ligand.  The primary structure of the catalytic domain of  human 5-LOX was similar to rabbit 15-LOX based  on the presence of an amino-terminal β-barrel  domain (calcium-binding site) and a carboxy-terminal α-helical domain containing iron (catalytic domain) with 80% homology of the sequence to human lipoxygenase26,27. Based on the Glide score, TC1 (Dihydroxy 
berberine) was identified as the best docked ligand in 
both COX and LOX enzymes in the presence and 
absence of ACD. Comparison of the docking score for 
the two compounds shows a common feature where 
the score is higher for the COX enzyme when 
compared to the LOX enzyme. The docking score 
reported for Diclofenac with COX-2 was -10.33 on 
docking with Glide software28 while for 5-LOX 
curcumin was reported with a score of -6.37329. The 
presence of ACD in the COX enzyme significantly 
lowers the docking score which indicates the possible 
binding of the ligand into the ACD binding site with 
higher affinity. The LOX enzymes docked with the 
ligands also exhibit a similar but opposite pattern  
of binding affinity. The ligand TC1 has a higher 
docking score for the RS7 co-crystallized protein as 
compared to the ACD bound enzyme. This indicates 
the binding of the ligand to a site distinct from  
the active site of the enzyme which is in accordance 
with experimental data16,18. COX enzyme inhibition 
usually leads to suicide inhibition in a relatively larger 
active site where once the inhibitor is bound the 
inhibition cannot be reversed. But in the case of  
LOX enzymes, the active site is hidden in a 
hydrophobic narrow pocket. The dihydroberberine 
has a higher affinity to the ACD binding site of LOX 
as demonstrated in the PDB ID 2P0M which indicates 
that it binds to the enzyme-substrate complex. As a 
result, both the enzyme and substrate are removed 
from the site of action. 
The ligand shows no hydrogen bonds with adjacent 
amino acids in enzyme active sites. The structure of TC1 
has no hydroxyl or amino groups for favourable 
hydrogen bond formation. This indicates that the binding 
of the ligands to the docking site depends on other 
hydrophobic or electrostatic interactions. The LOX 
enzymes have a smaller N-terminal domain and a larger 
iron-containing catalytic domain30. The iron remains in 
coordinate bonding with His550, His372, His367, 
Val671, and Asn554 while the sixth coordinate position 
faces an open cavity that is occupied by the docked 
ligand31. The docked poses reveal the proximity of TC1 
to the iron atom and its coordinate bonds with three 
histidine residues at positions 550, 372, and 367 in the 
active site of 5-LOX.The latter amino acids are involved 
with the bound RS7 in the homology model. 
The COX enzyme inhibitor binding has been 
predicted in the groove of the COX enzyme that 
involves Tyr 385, Trp387, Ala527, Ser530, Val349, 
Phe518, Leu352, Ser353, Tyr355, Val523, and Arg120 
residues32. As the data suggests the COX binding site is 
larger than for the LOX enzyme33. The proximity of 
TC1 to the active site of the proteins was found to be 
less in the presence of ACD compared to its absence. 
This observation could indicate the modification of the 
active site by the inhibitor ligand restricts the binding of 
ACD to the active site and also prevents the release of 
product from the active site as is expected for a mixed 
inhibitor. The secondary binding pocket that is formed 
in the COX-2 due to the replacement of Ile 523 in COX-
1 with the less bulky Val 523 seems to be occupied in 
the absence of ACD34. The proximity of the Trp387 and 
Tyr385 indicates the possibility of the hydrophobic 
interaction of the ligand in the presence of ACD as the 
bound ligand. 
The ADMET study results show that the compound 
TC1, dihydroberberine has a Human intestinal 
absorption rate of 97% which indicates that it would be 
well absorbed. The compound also shows medium 
permeability in Caco2 and MDCK cell models but poor 
absorption from the skin. The advantage would be that 
dihydroberberine has low absorption to the CNS and 
does not breach the blood-brain barrier. The compound 
has a strong binding to plasma proteins and could act as 
a disadvantage in drug distribution35 but recent reports36 
indicate that the plasma protein binding would not 
necessarily affect its efficacy. The drug efficacy is more 
dependent on the free drug concentration at the site of 




action and not elsewhere37 and can be increased by 
increasing permeation or metabolic stability or even 
reducing efflux. The compound shows positive for 
mutagenicity with a medium risk of cardiotoxicity but is 
largely non-carcinogenic. Zhu et al.38 have reported on 
the induction of apoptosis and DNA damage in human 
osteosarcoma cells which indicates the mutagenic 
property of the compound but against sarcoma cells. 
Anis et al.39 has also reported on the inhibition of 
carcinogenesis of berberine and its active form 
dihydroberberine. Dihydroberberine is found to be anti-
carcinogenic as it inhibits P-glycoprotein. The P-
glycoprotein is found overexpressed in cancer cells and 
inhibits the internalization of chemotherapeutic drugs40. 
Bansal et al.41 report on the significance of flavonoid 
secondary metabolite in chemotherapy for cancer. Such 
compounds are found to enhance bioavailability. The 
inhibition of P-glycoprotein thereby increases the 
therapeutic efficacy of the treatments as compared with 
standard P-glycoprotein inhibition by verapamil, and 
cyclosporine. Dihydroberberine also exhibits properties 
similar to other Non-Steroidal Anti-Inflammatory drugs 
(NSAID) and inhibits cytochrome P (CYP) 2C9. 
Compounds that indicate substrate activity for CYP2C9 
have been found to exhibit increased exposure leading to 
increased gastrointestinal and cardiovascular side 
effects42. The compound TC1 exhibits inhibition of most 
CYPs including CYP2C9 making it more desirable as a 
lead candidate for drug development. Interaction with 
the CYP 450 enzymes is not desirable in potential drug 
candidates. Dihydroberberine requires extended lead 
identification and pharmacophore-based modeling to 
develop into an effective drug candidate for anti-
inflammatory effect.The fact that has to be specifically 
noted is that Berberine has also been identified as a 
potential inhibitor of COVID-19 Main Protease (Mpro)43 
and Dihydroberberine is considered to be the active form 
of Berberine44. This implicates the activity of berberine 
as an anti-COVID agent which has several anti-
inflammatory actions45 like inhibition of pro-
inflammatory cytokines and dual LOX-COX inhibition. 
 Conclusion The compounds identified from the bioactive 
fraction of T. cordifolia were thus evaluated for their 
drug-likeness score and molecular properties to 
eliminate possible false positives in the development 
of suitable anti-inflammatory drug candidates. Five 
compounds with positive drug-likeness scores were 
further evaluated with in silico molecular docking 
studies with 5-LOX and COX-2 enzymes and the 
results indicate that TC1(dihydroberberine) shows the 
best binding energy as compared to the other four 
compounds for both enzymes. The binding pattern 
indicates the ability of dihydroberberine to bind to 
both the free enzyme and enzyme-substrate complex 
as evidenced earlier by kinetic studies in LOX 
enzymes. Dihydroberberine was then subjected to  
in vitro ADMET studies which reflect on the 
therapeutic potential of the compound and the need for 
further exhaustive studies for the development of an 
effective safer alternative to anti-inflammatory drugs 
with the possibility as a potential anti-COVID agent. 
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